Objective: Endoscopic ultrasound (EUS)-guided biliary drainage is evolving as an alternative technique in patients with failed endoscopic retrograde cholangiopancreatography. The objective of this study was to find out the outcome of EUS-guided choledochoduodenostomy in patients with malignant mid and lower end biliary obstruction with inaccessible papilla presenting at our center. Methods: The present study was a single-center prospective observational study. Data of all the patients who underwent choledochoduodensotomy from January 2014 to December 2015 were recorded. Outcome measures were technical success and clinical success. Technical success was defined as successful placement of stent in the biliary system; clinical success was defined as 50% reduction in bilirubin at 2 weeks. Complications during the procedure and follow-up were recorded. Results: A total of 10 patients underwent EUS-guided choledochoduodenostomy. Cause of biliary obstruction was pancreatic cancer in eight patients, two patients had carcinoma gallbladder with mid-common bile duct (CBD) block due to compression by metastatic lymph nodes, and one patient had ampullary carcinoma. Mean bilirubin value was 16.4 mg/dL (±3.2 mg/dL). Technical and clinical success were 100% and 90%, respectively. No immediate procedure-related complication was noticed. Two patients had stent migration during the follow-up. Conclusion: EUS-guided choledochoduodenostomy is an effective and safe alternative for rescuing biliary drainage in patients with mid and lower end malignant CBD block with inaccessible papilla.
of permanent external drainage. [4] Since endoscopic ultrasound (EUS)-guided bile duct puncture was described in 1996, [5] various reports regarding technical feasibility and complication rate of EUS-guided biliary drainage have been published. The potential benefits
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IntroductIon E ndoscopic retrograde cholangiopancreatography (ERCP) is the established procedure for biliary drainage in patients with malignant biliary obstruction. [1] Although the success rate of ERCP is more than 95%, ERCP may not be possible in patients with tumor invasion of the duodenum or the major papilla and postsurgical cases. [2, 3] Percutaneous transluminal biliary drainage (PTBD) is a conventional alternative procedure in such conditions, but is associated with complications of pain, bile leak, bleeding, and possibility of EUS-guided drainage over PTBD are single-stage procedure and internal drainage. The technique is still evolving with different success rate and complication rates across the studies, which may depend on indication of the procedure, type of procedure chosen, and the accessories used. The present study is our experience with EUS-guided transduodenal drainage in patients with mid and lower end common bile duct (CBD) obstruction.
Methods

Patients and methods
The present study is a prospective study conducted at a single tertiary care referral center (Sir Ganga Ram Hospital, New Delhi, India). Data of all the patients undergoing endoscopic biliary drainage for malignant biliary obstruction from January 2014 to December 2015 were prospectively collected. All the patients with malignant biliary obstruction and unresectable disease based on computed tomography, magnetic resonance imaging and EUS findings, and inaccessible papilla due to duodenal narrowing were considered for EUS-guided choledochoduodenostomy (CD). Informed consent was obtained from all the patients after explaining the technique and possible complications of EUS-guided CDS.
Technique of endoscopic ultrasound-CDS and stenting
A single interventional endoscopist (VS) experienced in EUS, who has performed more than 1500 EUS-guided fine-needle aspirations (FNAs) and more than 50 EUS-guided drainage procedures, performed all the EUS-guided biliary drainage procedures. All patients received prophylactic antibiotics. Intervention radiologist was informed before starting procedure, for the need of percutaneous drainage if the procedure fails, or radiological management of complication.
All the procedures were performed in prone position under conscious sedation with midazolam and pentazocine. Procedures carried out in the prone position as fluoroscopic imaging was a part of the procedure. Previous studies have shown that it is technically easier and safer to perform in the prone position. [6] EUS was performed with linear array echoendoscope (GFUCT180; Olympus Medical, Tokyo, Japan). Initial endoscopic surveillance was done to rule out duodenal lesions, precluding transduodenal drainage. CBD was focused from the first part of the duodenum, scope was turned counterclockwise, which would direct the probe and accessories toward liver hilum. In the first part of the duodenum, the echoendoscope was positioned in the long loop as it is the stable position. [7] Before planning EUS drainage, dilatation with controlled radial expansion balloon was not planned due to risk of perforation and bleeding. [8] Transduodenal puncture of CBD was done with 19Gneedle (Echo Tip 19A; Cook Endoscopy, Winston Salem, NC, USA) [ Figure 1a ], stylet was withdrawn, position was confirmed with bile aspiration, contrast was injected and cholangiogram was obtained. Subsequently, 0.035 inch/450-cm guidewire (Jagwire, Microvasive Endoscopy, Boston Scientific, Natick, MA, USA) was directed toward the intrahepatic radical, following which needle was withdrawn leaving wire in situ [ Figure 1b ]. Over-the-wire dilatation was performed with 6 Fr cystotome (Cysto Gastro Set; Endoflex, GmbH, Voerde, Germany) with coagulation current [ Figure 1c ], following which 6 cm fully covered self-expanding metal stent (Wallstent; Microvasive Endoscopy, Boston Scientific, Natick, MA, USA) was deployed, leaving 2 cm of stent in duodenum as a safeguard against internal migration in CBD [ Figure 1d ]. The entire procedure was performed under fluoroscopy.
After the procedures, all the patients were admitted for 24-48 h and were monitored for signs of internal bleeding, duodenal leak, and cholangitis. If there was no complication, clear liquids were allowed next day.
Inclusion and exclusion criteria
The procedure was performed only in patients with proven malignancy with mid and lower end CBD block.
Exclusion criteria were pregnancy, major organ failure, large volume ascites, poor cardiovascular status, coagulopathy (international normalized ratio >1.5), thrombocytopenia (platelet counts <50,000/μL), and refusal to consent. Outcome measures: Success and complications Outcome measures were technical success and functional success. Technical success was defined as successful deployment of the stent in CBD. Clinical success was defined as a reduction in bilirubin value by 50% at 2 weeks compared with the preprocedural value. All the complications during the procedures and during follow-up were recorded. During and after the procedure, patients were monitored for complications of internal bleeding, bile leak, and pneumoperitoneum. After the discharge, patients were followed up for the evaluation of persistent successful biliary drainage. Cross-sectional imaging was done during follow-up if indicated.
results
From January 2014 to December 2015, ten patients (6 males) underwent EUS-guided CDS [ Table 1 ]. Cause of biliary obstruction was pancreatic cancer in seven patients, two patients had carcinoma gallbladder with mid-CBD block due to compression by metastatic lymph nodes, and one patient had ampullary carcinoma. All the patients had inaccessible papilla due to tumor infiltration of the duodenum. Mean bilirubin value was 16.4 mg/dL (±3.2 mg/dL). The mean age was 58.6 (±4.2).
Technical success was 100%. In all the patients, wire-guided 6 Fr cystotome was used for dilatation; mean procedure time was 32 min (±12 min). No immediate procedure-related complication was noticed. Functional success was 90%. Jaundice improved after the procedure in all the patients except one who had liver metastasis. Bilirubin value decreased to 1.8 mg/dL (1.4 mg/dL) at 1-month follow-up. After a mean follow-up of 8 months (±3 months), survival was 60%, four patients died because of the underlying malignancy. Two patients had stent migration in duodenal lumen at 3 and 4 months after the initial procedure, which was taken out, and plastic stent was placed through the patent choledochoduodenal fistula [ Table 2 ].
dIscussIon
We found EUS-CDS safe and efficacious in patients with inaccessible papilla. EUS-guided cholangiography was first described by Wiersema et al. in 1996 , and first EUS-guided biliary drainage was described by Giovannini et al. [9] in 2001, and since that time many reports of EUS-guided biliary drainage have been published. EUS-guided biliary drainage is evolving technique, which needs comparison with existing modalities of biliary drainage. Success rate and complications of EUS-guided biliary drainage in lower end CBD block are comparable to ERCP. [10] In the large retrospective series by Dhir et al., success rate and complication rate for EUS-guided drainage (choledochoduodenostomy and antegrade procedures) were 93.26% and 8.65%, respectively, which were similar to ERCP group. Similarly, EUS-guided drainage has been compared with PTBD. A study by Artifon et al. found similar technical, functional success, complications, and quality of life score in patients treated with PTBD and EUS-CDS. Nearly 33% of patients treated with PTBD had external drain initially which was internalized at follow-up. [11] However, Bapaye et al. reported higher success rate (95% vs. 46%) and lower complication rate (20% vs. 46%) with EUS-guided drainage as compared to PTBD. [12] EUS-guided procedures include rendezvous procedure or drainage procedures which can be performed by either transmural (choledochoduodenostomy or hepaticogastrostomy [HPG]) or antegrade approach. Rendezvous procedure was not feasible in our cohort of patients due to the inaccessible papilla. EUS-guided choledochoduodenostomy and HPG were compared in the recent randomized controlled trial, with comparable technical and clinical success. [13] Artifon et al. reported technical success rates of HPG and choledochoduodenostomy (CD) in 96% and 91% of patients, respectively, and clinical success rates were 91% and 77%, respectively. The adverse events After creation of fistula, either plastic or metal stent can be used. Although direct comparative studies are not available, metal stent may be associated with lesser bile leak, pneumoperitoneum and bleed, due to mechanical compression and tight apposition of stent against the wall of fistula, moreover because of larger diameter, occlusion rate may be lower and decline in bilirubin may be sharper. Only covered stents should be used during choledochoduodenostomy to reduce the risk of bile or air leak, however, covered stent may increase the risk of stent migration. In the present study, two patients had stent migration during the follow-up, which was removed endoscopically, but at that time, we could notice patent fistula through which plastic stent was placed.
Limitation of the study is small sample size and data are limited to patients from a single center, which may reduce its generalizability. However, the strength of the study is that we have chosen similar patients in our study, and all the patients underwent biliary drainage with a similar technique, with similar set of accessories used in all the patients. Hence, we can conclude that in group of patients with mid and lower end CBD block and inaccessible papilla, EUS-guided choledochoduodenostomy is efficacious and safe technique.
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